Network Insights Methodology Whitepaper Get Access

Eli Lilly

PERSON Health Care / Pharmaceutical Products & Services Momentum 6.2ML Momentum Score (0-100). Weighted composite of 9 features: mention velocity, article breadth, relationship density, deal context, recency, market cap, enrichment completeness, mention concentration, entity type. NORMALPSI regime classification. QUIET (<0.3): baseline activity. NORMAL (0.3-0.5): typical deal flow. ELEVATED (0.5-0.7): above-average signals. HIGH (0.7-0.85): significant activity. EXTREME (>0.85): exceptional signal concentration. Primary: Spectral Shift

$34.1B revenue (2025), Indianapolis pharma giant Eli Lilly accelerated earnings 156% YoY as GLP-1 obesity drugs Mounjaro and Zepbound drove blockbuster growth. Recent $100M+ investment in AI scribe startup Abridge signals expansion into AI-powered clinical trial recruitment and drug development infrastructure.

Strategic venture investment in Abridge (AI clinical trial recruitment platform); partnership with Nvidia and healthcare insurers (Aetna, Cigna) for AI-enabled drug development and clinical operations.
0.09
PSI ScorePlocamium Signal Index - composite z-score from 5 orthogonal signals: news frequency, targeted sentiment, graph centrality, regulatory filings, and clinical trial activity.
6.2
MomentumML Momentum Score (0-100). Weighted composite of 9 features including mention velocity, article breadth, deal context, and relationship density. Retrained weekly.
1%
ConfidenceSignal confidence - percentage of PSI sub-signals with sufficient data (30+ observations). Higher confidence means the PSI score is based on more complete data.
41
ConnectionsDegree centrality - number of unique entities this entity co-occurs with in news signals and articles. Higher = more connected in the intelligence network.
Eli Lilly is graph community structure is reorganizing around this entity — relationship patterns are changing (primary driver: Spectral Shift).
Connected Entities
NYSE Morgan Stanley PlocamiumAI FDA AstraZeneca Nvidia Apple China M&A Americans Alphabet United States CEO Europe Amazon
Watch This Entity
PSI Intelligence
30-Day Trend
2026-05-19 2026-06-18 43 0 Degree Mentions
Signal Decomposition
Attention Cascade
3.333
Narrative Drift
0.073
Spectral Shift
410.320
Sentiment-Momentum Divergence
0.000
Source Concentration
0.222
Signal
Eli Lilly is graph community structure is reorganizing around this entity — relationship patterns are changing (primary driver: Spectral Shift).
Driver
Ranked #35 of 87 in Health Care — in line with sector peers. PSI down 0.25 from yesterday (0.33 -> 0.09).
Action
Baseline conditions. Continue standard monitoring cadence.
Peer Comparison
35 of 87
Sector Rank
+0.31
Peer Z-Score
60%
Sector Percentile
Network Analysis
41 Degree Centrality
Ego Network (top connections)
NYSE (weight 23.0)Morgan Stanley (weight 18.0)PlocamiumAI (weight 16.0)FDA (weight 16.0)AstraZeneca (weight 7.0)Nvidia (weight 7.0)Apple (weight 6.0)China (weight 5.0) NYSEMorgan StanleyPlocamiumAIFDAAstraZenecaNvidiaAppleChina Eli Lilly (degree 41) Eli Lilly
Centrality History
2026-05-19 2026-06-18 43 0 Degree Mentions
EntityWeight StatusFirst Seen
NYSE 23 NEW
Morgan Stanley 18 NEW
PlocamiumAI 16 NEW
FDA 16 NEW
AstraZeneca 7 NEW
Nvidia 7 NEW
Apple 6 NEW
China 5 NEW
M&A 5 NEW
Americans 5 NEW
Alphabet 5 NEW
United States 5 NEW
CEO 4 NEW
Europe 4 NEW
Amazon 4 NEW
Microsoft 4 NEW
Walmart 4 NEW
Merck 4 NEW
Bloomberg 4 NEW
Beijing 3 NEW
Novartis 3 NEW
Hong Kong 3 NEW
Berkshire Hathaway 3 NEW
Broadcom 3 NEW
Elon Musk 3 NEW
SEC 3 NEW
SpaceX 3 NEW
Tesla 3 NEW
HHS 3 NEW
European Union 2 NEW
Article Coverage (0)
DateLaneTitle
No Plocamium-authored coverage yet. This entity surfaces in upstream signals (news, filings, trials) but has not yet been a primary subject of a published article. Watch this entity to be alerted when one is published.

Request Access

Full PSI intelligence, network analysis, EDGAR filings, and predicted links require an access token.

Data as of 2026-06-18 ← Intelligence Network